ClinicalTrialsFinder

HGBL With MYC and BCL2 and/or BCL6 Rearrangements Clinical Trials in Tianjin

1 recruitingTianjin, China

Showing 1–1 of 1 trials

Recruiting
Phase 1

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

Diffuse Large B Cell LymphomaDLBCL, Nos Genetic SubtypesFollicular Lymphoma Grade 3B+3 more
Shanghai Exuma Biotechnology Ltd.18 enrolled1 locationNCT06830031